Citations for: Medroxyprogesterone. Toxicology Data Network. US National Library of Medicine [Online Database]

Entry Type
Name
Value
Parent Entry
Pharmacology Data Field
Elimination Half-Life (t1/2)
32-44 h (oral administration)
Medroxy­progesterone Acetate (API)
Pharmacology Data Field
Excretion
Most metabolites excreted in the urine as glucuronide conjugates with only minor amounts excreted as sulfates. Detectable amounts have been found in milk.
Medroxy­progesterone Acetate (API)
Pharmacology Data Field
Tmax
2-4 h
Medroxy­progesterone Acetate (API)
Toxicology Data Field
Carcinogenicity
There is sufficient evidence in experimental animals for carcinogenicity of MPA.
Medroxy­progesterone Acetate (API)
Pharmacology Data Field
Enzyme Interactions
  • Competitive inhibitor of 3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase II (3β-HSDII), which is essential for the biosynthesis of sex steroids and corticosteroids.
  • CYP3A4: substrate, inducer
  • CYP2C8, CYP2C9: inhibitor
Medroxy­progesterone Acetate (API)
Pharmacology Data Field
Indications
Used as a contraceptive and to treat secondary amenorrhea, abnormal uterine bleeding, pain associated with endometriosis, endometrial and renal cell carcinomas, paraphilia in males, GnRH-dependent forms of precocious puberty, as well as to prevent endometrial changes associated with estrogens.
Medroxy­progesterone Acetate (API)